# Preventing Alzheimer’s Before Symptoms: The Rise of Tau-Targeting Vaccines > Explore the shift from amyloid to tau-targeting vaccines for Alzheimer's prevention. Learn about UNM's pT181 trial and Nuravax's dual-phase initiative. - Source: https://longevity.nicheflash.com/blogs/preventing-alzheimers-tau-targeting-vaccines-longevity - Publisher: Longevity Blogs - Published: 2026-08-17 - Updated: 2026-08-17 - UNM researchers launched a Phase 1 human trial in July 2025 for a Qβ virus-like particle vaccine targeting phosphorylated Tau (pT181), distinct from prior amyloid-focused therapies. - Nuravax initiated the DU-PRISM Phase 1 trial in November 2025, utilizing a MultiTEP platform to concurrently target Amyloid-Beta and Tau proteins. - Current immunotherapies prioritize "conformational selectivity," aiming to neutralize toxic protein shapes without triggering autoimmune encephalitis seen in earlier attempts. - The clinical focus has shifted decisively toward the asymptomatic preclinical phase, aligning with longevity goals of delaying cognitive aging indefinitely. ## Why are Alzheimer’s vaccines targeting tau instead of amyloid? Alzheimer’s vaccines are shifting focus from amyloid plaques to tau protein because tau pathology correlates more accurately with neuronal death and cognitive decline. For decades, drug development centered on cleaning up Amyloid-Beta plaques, but evidence suggests these accumulations appear decades before symptoms arise, making late-stage clearance insufficient for prevention. **Tau neurofibrillary tangles**, which are internal protein clumps that disrupt cellular transport, serve as a better predictor of disease progression. This strategic pivot represents a paradigm shift from reactive treatment to proactive immunization. Instead of attempting to clear waste after damage is done, new approaches aim to "educate" the immune system to patrol for and neutralize toxic protein structures before they reach symptomatic levels. This preventative approach is critical for longevity medicine, where the goal is maintaining cognitive health well into advanced age. ## How does the UNM pT181 vaccine work differently than previous attempts? The University of New Mexico Health Science Center (UNM) developed a vaccine that uses a Qβ bacteriophage shell to display a specific pathological modification of Tau called pT181. Unlike earlier broad-spectrum vaccines that risked attacking healthy native Tau, this design ensures **conformational selectivity**, meaning it targets only the misfolded, toxic version of the protein. Key innovations in this candidate include: - **Mechanism:** The Qβ bacteriophage mimics a viral structure, triggering a robust immune response without requiring harsh chemical adjuvants, thereby reducing inflammatory risks. - **Specificity:** By focusing on phosphorylated Tau at threonine 181, the vaccine minimizes the risk of autoimmune encephalitis, a severe side effect observed in previous candidates like AADvac1. - **Status:** Following successful preservation of memory in mouse and non-human primate models, UNM launched a human Phase 1 clinical trial in June/July 2025, with findings reported in *Alzheimer's & Dementia*. > The distinction lies not just in the target, but in the precision of the immune response. We are moving beyond general amyloid clearance to educating the immune system to recognize specific toxic conformational changes. ## What is Nuravax’s dual-target strategy for early prevention? Nuravax is pursuing a "dual-target" strategy through its vaccine candidate, DUVAX, designed specifically for the asymptomatic preclinical phase of Alzheimer’s disease. In November 2025, the company initiated the **DUPRISM Phase 1 trial** to test this approach in humans. The core of this strategy involves the **MultiTEP platform**, which elicits high-affinity antibodies against both Amyloid-Beta and Tau simultaneously. This dual-action hypothesis posits that intervening on both pathways during the earliest stages of pathology offers the highest probability of preventing clinical dementia. Securing a $3 million NIH grant under the Fast-Track Program in May 2025 underscores the industry’s confidence in this early-intervention model for genetic-at-risk populations. ## What safety concerns have emerged with newer tau immunotherapies? Historical risks associated with active immunotherapy for Alzheimer’s included significant neuroinflammation, such as meningitis or meningoencephalitis, when vaccines failed to distinguish between healthy and diseased proteins. Current developments explicitly address these safety profiles by emphasizing selective antibody binding. Global trials, including expanded recruitment by Scottish Brain Sciences across UK sites, are closely monitoring immunogenicity in elderly volunteers over age 50. Recent data published in *Lancet Regional Health - Europe* highlights that newer candidates successfully mitigate inflammation by ensuring the immune system attacks only the "bad" shapes of the protein while leaving essential functional Tau intact. ## Which clinical trials are currently defining the landscape of tau prevention? The following table summarizes key active or recently launched initiatives focusing on preventative immunotherapy for cognitive decline as of late 2025 and early 2026. | Institution / Company | Vaccine Candidate | Mechanism | Clinical Status | | --- | --- | --- | --- | | University of New Mexico (UNM) | Qβ VLP Vaccine | Targets pT181 Tau epitope via bacteriophage shell | Phase 1 Launched (June/July 2025) | | Nuravax | DUVAX | Dual-target: Amyloid-Beta & Tau via MultiTEP | Phase 1 Trial Initiated (Nov 2025) | | Scottish Brain Sciences | Tau Immunotherapies | Safety & Immunogenicity profiling | Recruitment Expanding (Late 2025) | These developments mark a departure from the "clean-up" mentality of the past decade. By targeting the root drivers of cognitive decline during the asymptomatic phase, researchers are laying the groundwork for true preventative neurology. ## References 1. [Alzheimer's & Dementia Journal (March 2025)](https://www.alzheimersanddementia.com/) 2. [Lancet Regional Health - Europe (2025/2026)](https://www.thelancet.com/journals/lanepe/home)